12/4/2024

Janusmed kön och genus

Janusmed kön och genus – linaklotid

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Linaklotid

Linaklotid

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Kim YS, Kim N. Sex-Gender Differences in Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2018;24(4):544-558.

  2. Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther. 2013;344(1):196-206.

  3. Constella (linaclotide). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2019-03-21, cited 2019-06-04].

  4. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107(11):1702-12.

  5. Constella (linaclotide). EPAR Public assessment report [updated 2012-09-20, cited 2019-06-04].

  6. Schoenfeld P, Lacy BE, Chey WD, Lembo AJ, Kurtz CB, Reasner DS et al. Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Am J Gastroenterol. 2018;113(1):105-114.

  7. Food and Drug Administration (FDA). NDA Review - Linzess (linaclotide) capsules. Drugs@FDA [www]. [updated 2017-01-25, cited 2019-06-04].

  8. Food and Drug Administration (FDA). Summary Review - Linzess (linaclotide) Capsules. Drugs@FDA [www]. [updated 2012-10-04, cited 2019-06-04].

  9. Nee JW, Johnston JM, Shea EP, Walls CE, Tripp K, Shiff S et al. Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis. Expert Rev Gastroenterol Hepatol. 2019;13(4):397-406.

  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-05-28.]

  1. Kim YS, Kim N. Sex-Gender Differences in Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2018;24(4):544-558.
  2. Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther. 2013;344(1):196-206.
  3. Constella (linaclotide). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2019-03-21, cited 2019-06-04].
  4. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107(11):1702-12.
  5. Constella (linaclotide). EPAR Public assessment report [updated 2012-09-20, cited 2019-06-04].
  6. Schoenfeld P, Lacy BE, Chey WD, Lembo AJ, Kurtz CB, Reasner DS et al. Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Am J Gastroenterol. 2018;113(1):105-114.
  7. Food and Drug Administration (FDA). NDA Review - Linzess (linaclotide) capsules. Drugs@FDA [www]. [updated 2017-01-25, cited 2019-06-04].
  8. Food and Drug Administration (FDA). Summary Review - Linzess (linaclotide) Capsules. Drugs@FDA [www]. [updated 2012-10-04, cited 2019-06-04].
  9. Nee JW, Johnston JM, Shea EP, Walls CE, Tripp K, Shiff S et al. Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis. Expert Rev Gastroenterol Hepatol. 2019;13(4):397-406.
  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-05-28.]